

Bovilis Nasalgen-C (--) - Nasal spray, lyophilisate and solvent for suspension

Authorised

- Bovine coronavirus, strain CA25, Live

Product identification

Medicine name:

Bovilis Nasalgen-C (--) - Nasal spray, lyophilisate and solvent for suspension

Active substance:

Bovine coronavirus, strain CA25, Live

Target species:

Cattle

Route of administration:

Nasal use

Product details

Active substance and strength:

Bovine coronavirus, strain CA25, Live

Presentation_strength: $\geq 5.4 \log_{10} \text{TCID}_{50} \leq 7.8 \log_{10} \text{TCID}_{50}$ Reference:Hse Index:0

Pharmaceutical form:

Nasal spray, lyophilisate and solvent for suspension

Withdrawal period by route of administration:**Nasal use:**

- Cattle

Anatomical therapeutic chemical veterinary (ATCvet) codes:

QI02AD10

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:

Valid

Authorised in:

Austria , Belgium , Bulgaria , Croatia , Cyprus , Czechia , Denmark , Estonia , Finland , France , Germany , Greece , Hungary , Iceland , Ireland , Italy , Latvia , Liechtenstein , Lithuania , Luxembourg , Malta , Netherlands , Norway , Poland , Portugal , Romania , Slovakia , Slovenia , Spain , Sweden , United Kingdom (Northern Ireland)

Package description:

Packaging:Lyophilisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 1 vial + solvent: 1 vial, Content:Lyophilisate: 50 doses + solvent: 100 ml

Packaging:Lyophilisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 1 vial+ solvent: 1 vial, Content:Lyophilisate: 20 doses + solvent: 40 ml

Packaging:Lyophilisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 5 vials + solvent: 5 vials, Content:Lyophilisate: 5 x 10 doses + solvent: 5 x 20 ml

Packaging:Lyophilisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 5 vials + solvent: 5 vials, Content:Lyophilisate: 5 x 5 doses + solvent: 5 x 10 ml

Packaging:Lyophilisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 5 vials + solvent: 5 vials, Content:Lyophilisate: 5 doses; solvent: 10 ml

Packaging:Lyophilisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 1 vial + solvent: 1 vial, Content:Lyophilisate: 10 doses + solvent: 20 ml

Packaging:Lyophilisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 1 vials + solvent: 1 vial, Content:Lyophilisate: 5 doses + solvent: 10 ml

Packaging:Lyophilisate: vial (glass); solvent: vial (glass), Package_size:Lyophilisate: 1 vial + solvent: 1 vial, Content:Lyophilisate: 1 dose; solvent: 2 ml

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:

Full application - New active substance (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:

Intervet International B.V.

Marketing authorisation date:

This information is not available for this product.

Manufacturing sites for batch release:

INTERVET INTERNATIONAL B.V.

Responsible authority:

European Commission

Authorisation number:

This information is not available for this product.

Date of authorisation status change:

31/03/2023

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Combined File of all Documents

English (PDF)

Published on: 21/02/2024

Download

ema-puar-v5906-bovilis-nasalgen-c-en.pdf

Source URL: <https://medicines.health.europa.eu/veterinary/600000984519>